Jeffy G Mattathil

Dr. Jeffy G Mattathil

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JMJeffy G Mattathil
Jeffy G Mattathil
WVWilliam G. Valiant
William G. Valiant
MMMary J. Mattapallil
Mary J. Mattapallil
MWMichelle Walker
Michelle Walker
YHYan-Jang S. Huang
Yan-Jang S. Huang
Joseph MattapallilJoseph Mattapallil
Joseph Mattapallil
Structural and functional homologies between the Zika and Dengue viruses’ envelope proteins raise the possibility that cross-reactive antibodies induced following Zika virus infection might enhance subsequent Dengue infection. Using the rhesus macaque model we show that prior infection with Zika virus leads to a significant enhancement of Dengue-2 viremia that is accompanied by neutropenia, lympocytosis, hyperglycemia, and higher reticulocyte counts, along with the activation of pro-inflammatory monocyte subsets and release of inflammatory mediators. Zika virus infection induced detectable Dengue cross-reactive serum IgG responses that significantly amplified after Dengue-2 virus infection. Serum from Zika virus immune animals collected prior to Dengue-2 infection showed significant capacity for in vitro antibody dependent enhancement of Dengue-1, 2, 3 and 4 serotypes suggesting that pre-existing immunity to Zika virus could potentially enhance infection by heterologous Dengue serotypes. Our results provide first in vivo evidence that prior exposure to Zika virus infection can enhance Dengue infection, which has implications for understanding pathogenesis and the development of vaccines.

31 May 2023 in Viruses
Verified
Journal Article
Open access
PDF file
BSBobban Subhadra
Bobban Subhadra
RARagini Agrawal
Ragini Agrawal
VPVirender Kumar Pal
Virender Kumar Pal
ACAgnes Laurence Chenine
Agnes Laurence Chenine
JMJeffy G Mattathil
Jeffy G Mattathil
ASAmit Singh
Amit Singh
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has so far infected 762 million people with over 6.9 million deaths worldwide. Broad-spectrum viral inhibitors that block the initial stages of infection by reducing virus binding and proliferation, thereby reducing disease severities, are still an unmet global medical need. We studied Bi121, which is a standardized polyphenolic-rich compound isolated from Pelargonium sidoides, against recombinant vesicular stomatitis virus (rVSV)-pseudotyped SARS-CoV-2S (mutations in the spike protein) of six different variants of SARS-CoV-2. Bi121 was effective at neutralizing all six rVSV-ΔG-SARS-CoV-2S variants. The antiviral activity of Bi121 was also assessed against SARS-CoV-2 variants (USA WA1/2020, Hongkong/VM20001061/2020, B.1.167.2 (Delta), and Omicron) in Vero cells and HEK-ACE2 cell lines using RT-qPCR and plaque assays. Bi121 showed significant antiviral activity against all the four SARS-CoV-2 variants tested, suggesting a broad-spectrum activity. Bi121 fractions generated using HPLC showed antiviral activity in three fractions out of eight against SARS-CoV-2. The dominant compound identified in all three fractions using LC/MS/MS analysis was Neoilludin B. In silico structural modeling studies with Neoilludin B showed that it has a novel RNA-intercalating activity toward RNA viruses. In silico findings and the antiviral activity of this compound against several SARS-CoV-2 variants support further evaluation as a potential treatment of COVID-19.

7 March 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
JMJeffy G Mattathil
Jeffy G Mattathil
AVAsisa Volz
Asisa Volz
OOOlusegun O. Onabajo
Olusegun O. Onabajo
SMSean Maynard
Sean Maynard
SBSandra L. Bixler
Sandra L. Bixler
Joseph MattapallilJoseph Mattapallil
Joseph Mattapallil
Human immunodeficiency virus (HIV) is a mucosally transmitted virus that causes immunodeficiency and AIDS. Developing efficacious vaccines to prevent infection is essential to control the epidemic. Protecting the vaginal and rectal mucosa, the primary routes of HIV entry has been a challenge given the significant compartmentalization between the mucosal and peripheral immune systems. We hypothesized that direct intranodal vaccination of mucosa associated lymphoid tissue (MALT) such as the readily accessible palatine tonsils could overcome this compartmentalization. Here we show that rhesus macaques primed with plasmid DNA encoding SIVmac251-env and gag genes followed by an intranodal tonsil MALT boost with MVA encoding the same genes protects from a repeated low dose intrarectal challenge with highly pathogenic SIVmac251; 43% (3/7) of vaccinated macaques remained uninfected after 9 challenges as compared to the unvaccinated control (0/6) animals. One vaccinated animal remained free of infection even after 22 challenges. Vaccination was associated with a ~2 log decrease in acute viremia that inversely correlated with anamnestic immune responses. Our results suggest that a combination of systemic and intranodal tonsil MALT vaccination could induce robust adaptive and innate immune responses leading to protection from mucosal infection with highly pathogenic HIV and rapidly control viral breakthroughs.

17 November 2023 in Viruses
Verified
Journal Article
Open access
PDF file
BSBobban Subhadra
Bobban Subhadra
RARagini Agrawal
Ragini Agrawal
VPVirender Kumar Pal
Virender Kumar Pal
ACAgnes Laurence Chenine
Agnes Laurence Chenine
JMJeffy G Mattathil
Jeffy G Mattathil
ASAmit Singh
Amit Singh
We would like to thank Dr. Žarko Kulić